Acupuncture could relieve joint pain linked to breast cancer treatments

Washington, Mar 5 (ANI): Acupuncture could be an effective therapy for joint pain and stiffness in breast cancer patients who are being treated with commonly used hormonal therapies, says a new study.

Joint pain and stiffness are common side effects of aromatase inhibitor therapy, in which the synthesis of estrogen is blocked.

Researchers at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center, led the new study.

It was previously shown that the therapy, which is a common and effective treatment for early-stage, hormone-receptor-positive breast cancer in post-menopausal women, causes some joint pain and stiffness in half of women being treated.

“Since aromatase inhibitors have become an increasingly popular treatment option for some breast cancer patients, we aimed to find a non-drug option to manage the joint issues they often create, thereby improving quality of life and reducing the likelihood that patients would discontinue this potentially life-saving treatment,” said Dr. Dawn Hershman, senior author of the paper.

To explore the effects of acupuncture on aromatase inhibitor-associated joint pain, researchers randomly assigned 43 women to receive either true acupuncture or sham acupuncture twice a week for six weeks.

Sham acupuncture, which was used to control for a potential placebo effect, involved superficial needle insertion at body points not recognized as true acupuncture points.

All participants were receiving an aromatase inhibitor for early breast cancer, and all had reported musculoskeletal pain.

In women treated with true acupuncture, it was shown that they experienced significant improvement in joint pain and stiffness over the course of the study.

Pain severity declined, and overall physical well being improved.

In addition, 20 percent of the patients who had reported taking pain relief medications reported that they no longer needed to take these medications following acupuncture treatment.

However, no such improvements were reported in women who were treated with the sham acupuncture.

“This study suggests that acupuncture may help women manage the joint pain and stiffness that can accompany aromatase inhibitor treatment,” said Dr. Katherine D. Crew, first author of the paper.

“To our knowledge, this is the first randomized, placebo-controlled trial establishing that acupuncture may be an effective method to relieve joint problems caused by these medications. However, results still need to be confirmed in larger, multicenter studies,” she added.

The results of the study were published in the Journal of Clinical Oncology. (ANI)

Scientists provide new insights into endometriosis

London, Jan 18 (ANI): Scientists from Northwestern University’s Feinberg School of Medicine have found vital clues that may help explain the cause of endometriosis.

Endometriosis is a chronic disease characterized by infertility and chronic pelvic pain during intercourse.

The study led by Serdar Bulun, M.D., George H. Gardner Professor of Clinical Gynecology at Northwestern University’s Feinberg School of Medicine, have discovered key epigenetic abnormalities in endometriosis and identified existing chemicals that now help treat it.

These abnormalities result from epigenetic defects that occur very early on during embryonic development and may be the result of early exposure to environmental toxins

One of the abnormalities he discovered is the presence of the enzyme aromatase — which produces estrogen — in endometriosis, the diseased tissue that exists on pelvic organs and mimics the uterine lining.

As a result, women with endometriosis have excessive estrogen in this abnormal tissue found on surfaces of pelvic organs such as the ovaries.

Bulun found the protein SF1 that produces aromatase, which is supposed to be shut down, is active in endometriosis.

“Estrogen is like fuel for fire in endometriosis. “It triggers the endometriosis and makes it grow fast,” Bulun said.

Bulun launched clinical trials in testing aromatase inhibitors — currently used in breast cancer treatment — for women with endometriosis.

The drug blocks estrogen formation and secondarily improves progesterone responsiveness.

“We came up with a new treatment of choice for post-menopausal women with endometriosis,” Bulun said. Moreover, treatment with an aromatase inhibitor is a very good option for premenopausal women with endometriosis not responding to existing treatments, he said.

Another molecular abnormality Bulun found is that women with endometriosis have a progesterone receptor that is inappropriately turned off.

In the absence of appropriate progesterone action, endometriosis tissue remains inflamed and continues to grow.

“This may be a disease that women are born with. Perhaps when a baby girl is born, it has already been determined that she is predisposed to have endometriosis,” Bulun said.

“Maybe research can now be directed toward the fetal origins of the disease and raise the awareness of how the disease develops,” he added.(ANI)